A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial
2015; Oxford University Press; Volume: 36; Issue: 31 Linguagem: Inglês
10.1093/eurheartj/ehv191
ISSN1522-9645
AutoresAlexandra J. Lansky, Joachim Schöfer, Didier Tchetchè, Pieter R. Stella, Cody Pietras, Helen Parise, Kevin Abrams, John K. Forrest, Michael Cleman, Jochen Reinöhl, Thomas Cuisset, Daniel J. Blackman, Gil Bolotin, Stefan G. Spitzer, Utz Kappert, Martine Gilard, Thomas Modine, David Hildick‐Smith, Michael Haude, Pauliina Margolis, Adam M. Brickman, Szilárd Vörös, Andreas Baumbach,
Tópico(s)Cardiac Imaging and Diagnostics
ResumoAimsTo evaluate the safety, efficacy, and performance of the TriGuard™ HDH Embolic Deflection Device (TriGuard) compared with no cerebral protection in patients undergoing transcatheter aortic valve implantation (TAVI).
Referência(s)